|
Clinicopathologic variables and outcomes in elderly colorectal cancer patients with microsatellite instability and multiple primary malignancies. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Legend Biotech; Legend Biotech |
Travel, Accommodations, Expenses - NanoCarrier |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Cancer Commons; Ipsen; Legend Biotech |
Research Funding - Agios (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); ImmuneSensor Therapeutics (Inst); MedImmune (Inst); Merck Serono (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst) |
| |
|
Stock and Other Ownership Interests - Johnson & Johnson/Janssen |